Vassyl Lonchyna to Combined Modality Therapy
This is a "connection" page, showing publications Vassyl Lonchyna has written about Combined Modality Therapy.
Connection Strength
0.017
-
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995 Aug; 13(8):1880-92.
Score: 0.006
-
Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. Ann Thorac Surg. 1994 Aug; 58(2):290-4; discussion 294-5.
Score: 0.006
-
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993 Jan; 105(1):97-104; discussion 104-6.
Score: 0.005